AbbVie Seeks $8 Billion Debt for Apogee Therapeutics Acquisition

AbbVie Inc., a global biopharmaceutical company known for its immunology and oncology treatments, is seeking to raise a minimum of $8 billion through an investment-grade bond offering. This significant debt financing is intended to fund a portion of its previously announced acquisition of Apogee Therapeutics Inc. The total value of the Apogee Therapeutics acquisition is approximately $30 billion, with AbbVie agreeing to acquire all outstanding shares of Apogee for $90 per share in cash, plus one non-tradable contingent value right (CVR) per share. The CVR could provide an additional payment of up to $10 per share, contingent on the achievement of certain regulatory milestones related to Apogee's lead drug candidate, Siglec-15 (nirgocelestat), for idiopathic pulmonary fibrosis (IPF).

The bond offering, which is being managed by several major financial institutions, aims to secure capital from investors who are willing to lend to companies with strong credit ratings. Investment-grade bonds are considered less risky than high-yield or "junk" bonds, typically offering lower interest rates. By issuing these bonds, AbbVie is leveraging the debt markets to finance a substantial part of the acquisition cost, rather than relying solely on its existing cash reserves or equity financing. This strategy can help manage the financial impact of the large transaction and potentially optimize AbbVie's capital structure.

Apogee Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing novel therapies for serious and complex diseases. Its lead program, nirgocelestat, is being developed for IPF, a chronic, progressive lung disease with limited treatment options. The acquisition of Apogee represents a significant strategic move for AbbVie, aiming to bolster its pipeline and expand its presence in the respiratory and immunology therapeutic areas. The deal is expected to close in the second half of 2024, subject to customary closing conditions, including regulatory approvals and the tender of a majority of Apogee's outstanding shares.

The $8 billion debt issuance underscores the substantial financial commitment AbbVie is making to integrate Apogee's assets and intellectual property. This financing strategy is a common practice for large-scale mergers and acquisitions, allowing companies to spread the cost over time and maintain financial flexibility. Investors in the bond offering will be assessing AbbVie's long-term financial health and its ability to generate sufficient cash flow to service the debt, alongside the strategic rationale and potential return on investment from the Apogee acquisition. The success of the bond offering will be an indicator of market confidence in AbbVie's financial strategy and its growth prospects following the integration of Apogee Therapeutics.